Investor optimism has waned as final minutes from uniQure’s pre-BLA meeting with the FDA convey that data from the company’s ...
The gene therapy company received final meeting minutes from the FDA regarding a pre-Biologics License Application for ...
The FDA is expected to decide on treatments for breast cancer, EBV+ post-transplant lymphoproliferative disease, focal segmental glomerulosclerosis, presbyopia, and severe allergic reactions.
UniQure shares fell Thursday after the gene therapy company said its Huntington's disease drug hit more regulatory roadblocks. Shares of the Lexington, Mass., company fell 15% early Thursday, to ...
Since November 2024, Fucaso has been accessible in Hong Kong through the Named Patient Programme (NPP). Following this approval, IASO Bio plans to expand its "Manufactured in Nanjing, Supplied ...
In case you haven't guessed it already, the big thing to wait on before buying any shares of Summit Therapeutics is the FDA's ...
BLA bomber targets paramilitary headquarters in Pakistan, resulting in multiple deaths and a subsequent gunfight with militants.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback